MedTrace Logo

A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer

NCT04380012 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-07-15

No results posted yet for this study

Summary

To Observe the Efficacy and Safety of Pyrotinib Maleate in Patients With HER2-positive Advanced Colorectal Cancer

Conditions

Interventions

DRUG

Pyrotinib

Pyrotinib as interventions were used in patients with HER2-positive advanced colorectal cancer

DRUG

Pyrotinib in combination with trastuzumab

Pyrotinib in combination with trastuzumab as interventions were used in patients with HER2-positive advanced colorectal cancer

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    collaborator OTHER

  • Zhejiang Provincial People's Hospital

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-17
Primary Completion
2021-12-17
Completion
2022-06-17

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04380012 on ClinicalTrials.gov